Literature DB >> 23255807

Tra2-mediated recognition of HIV-1 5' splice site D3 as a key factor in the processing of vpr mRNA.

Steffen Erkelenz1, Gereon Poschmann, Stephan Theiss, Anja Stefanski, Frank Hillebrand, Marianne Otte, Kai Stühler, Heiner Schaal.   

Abstract

Small noncoding HIV-1 leader exon 3 is defined by its splice sites A2 and D3. While 3' splice site (3'ss) A2 needs to be activated for vpr mRNA formation, the location of the vpr start codon within downstream intron 3 requires silencing of splicing at 5'ss D3. Here we show that the inclusion of both HIV-1 exon 3 and vpr mRNA processing is promoted by an exonic splicing enhancer (ESE(vpr)) localized between exonic splicing silencer ESSV and 5'ss D3. The ESE(vpr) sequence was found to be bound by members of the Transformer 2 (Tra2) protein family. Coexpression of these proteins in provirus-transfected cells led to an increase in the levels of exon 3 inclusion, confirming that they act through ESE(vpr). Further analyses revealed that ESE(vpr) supports the binding of U1 snRNA at 5'ss D3, allowing bridging interactions across the upstream exon with 3'ss A2. In line with this, an increase or decrease in the complementarity of 5'ss D3 to the 5' end of U1 snRNA was accompanied by a higher or lower vpr expression level. Activation of 3'ss A2 through the proposed bridging interactions, however, was not dependent on the splicing competence of 5'ss D3 because rendering it splicing defective but still competent for efficient U1 snRNA binding maintained the enhancing function of D3. Therefore, we propose that splicing at 3'ss A2 occurs temporally between the binding of U1 snRNA and splicing at D3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255807      PMCID: PMC3571381          DOI: 10.1128/JVI.02756-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

Authors:  T O Tange; C K Damgaard; S Guth; J Valcárcel; J Kjems
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

3.  Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs.

Authors:  Dibyakanti Mandal; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

4.  Exon definition complexes contain the tri-snRNP and can be directly converted into B-like precatalytic splicing complexes.

Authors:  Marc Schneider; Cindy L Will; Maria Anokhina; Jamal Tazi; Henning Urlaub; Reinhard Lührmann
Journal:  Mol Cell       Date:  2010-04-23       Impact factor: 17.970

5.  A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H.

Authors:  S Jacquenet; A Méreau; P S Bilodeau; L Damier; C M Stoltzfus; C Branlant
Journal:  J Biol Chem       Date:  2001-08-28       Impact factor: 5.157

6.  RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element.

Authors:  P S Bilodeau; J K Domsic; A Mayeda; A R Krainer; C M Stoltzfus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA.

Authors:  S Kammler; C Leurs; M Freund; J Krummheuer; K Seidel; T O Tange; M K Lund; J Kjems; A Scheid; H Schaal
Journal:  RNA       Date:  2001-03       Impact factor: 4.942

8.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  The HIV-1 major splice donor D1 is activated by splicing enhancer elements within the leader region and the p17-inhibitory sequence.

Authors:  Corinna Asang; Steffen Erkelenz; Heiner Schaal
Journal:  Virology       Date:  2012-06-30       Impact factor: 3.616

10.  Formation of trans-activation competent HIV-1 Rev:RRE complexes requires the recruitment of multiple protein activation domains.

Authors:  Dirk Hoffmann; Doreen Schwarck; Carina Banning; Matthias Brenner; Lakshmikanth Mariyanna; Marcel Krepstakies; Michael Schindler; David P Millar; Joachim Hauber
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

View more
  18 in total

1.  Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels.

Authors:  Masako Nomaguchi; Naoya Doi; Yosuke Sakai; Hirotaka Ode; Yasumasa Iwatani; Takamasa Ueno; Yui Matsumoto; Yasuyuki Miyazaki; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Analysis of Competing HIV-1 Splice Donor Sites Uncovers a Tight Cluster of Splicing Regulatory Elements within Exon 2/2b.

Authors:  Anna-Lena Brillen; Lara Walotka; Frank Hillebrand; Lisa Müller; Marek Widera; Stephan Theiss; Heiner Schaal
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  Genomic HEXploring allows landscaping of novel potential splicing regulatory elements.

Authors:  Steffen Erkelenz; Stephan Theiss; Marianne Otte; Marek Widera; Jan Otto Peter; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

4.  Profiling of cis- and trans-acting factors supporting noncanonical splice site activation.

Authors:  Steffen Erkelenz; Gereon Poschmann; Johannes Ptok; Lisa Müller; Heiner Schaal
Journal:  RNA Biol       Date:  2020-08-05       Impact factor: 4.652

5.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

6.  Balanced splicing at the Tat-specific HIV-1 3'ss A3 is critical for HIV-1 replication.

Authors:  Steffen Erkelenz; Frank Hillebrand; Marek Widera; Stephan Theiss; Anaam Fayyaz; Daniel Degrandi; Klaus Pfeffer; Heiner Schaal
Journal:  Retrovirology       Date:  2015-03-28       Impact factor: 4.602

7.  Differential Effects of Tra2ß Isoforms on HIV-1 RNA Processing and Expression.

Authors:  Craig Platt; Maria Calimano; Josip Nemet; Jodi Bubenik; Alan Cochrane
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

8.  Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication.

Authors:  Lulzim Shkreta; Marco Blanchette; Johanne Toutant; Emmanuelle Wilhelm; Brendan Bell; Benjamin A Story; Ahalya Balachandran; Alan Cochrane; Peter K Cheung; P Richard Harrigan; David S Grierson; Benoit Chabot
Journal:  Nucleic Acids Res       Date:  2017-04-20       Impact factor: 16.971

9.  Succession of splicing regulatory elements determines cryptic 5΄ss functionality.

Authors:  Anna-Lena Brillen; Katrin Schöneweis; Lara Walotka; Linda Hartmann; Lisa Müller; Johannes Ptok; Wolfgang Kaisers; Gereon Poschmann; Kai Stühler; Emanuele Buratti; Stephan Theiss; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2017-04-20       Impact factor: 16.971

10.  A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction.

Authors:  Marek Widera; Frank Hillebrand; Steffen Erkelenz; Ananda Ayyappan Jaguva Vasudevan; Carsten Münk; Heiner Schaal
Journal:  Retrovirology       Date:  2014-08-29       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.